Skip to content

The study to evaluate the efficacy and safety of Radiofrequency device (INDIBATM) 448 kHz for reduction in visceral fat

The study to evaluate the efficacy and safety of Radiofrequency device (INDIBATM) 448 kHz for reduction in visceral fat

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260401007
Enrollment
25
Registered
2026-04-01
Start date
2022-09-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with unwanted visceral fat 448 KHz, visceral fat reduction, radiofrequency

Interventions

Volunteers will be treated using a monopolar radiofrequency system operating at a frequency of 448 kHz. A resistive electrode (stainless steel applicator) will be applied directly to the participants
Experimental Device
Radiofrequency

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age 30 - 55 years 2. Body mass index (BMI) 18.5 - 24.9 kg/m2

Exclusion criteria

Exclusion criteria: 1. Participants with body weight changes greater than 3 kg within the past month 2. Participants who are pregnant, within 3 months postpartum, breastfeeding, or planning to become pregnant 3. Participants with a history of surgery in the study area within the past 1 year 4. Participants with a history of implanted metal devices, intrauterine devices (IUDs), cardiac - pacemakers, or electrically powered medical devices 5. Participants with wounds, skin infections, or dermatologic conditions at the study site 6. Participants with psychiatric disorders who are unable to remain still or cooperate during device use 7. Participants with a history of cancer, diabetes mellitus, or chronic kidney disease 8. Participants with abdominal hernia, peripheral vascular disease, heart disease, epilepsy, or any condition deemed by the investigator to pose a safety risk for study participation

Design outcomes

Primary

MeasureTime frame
Body weight Baseline, 1 wk, 4 wk, 12 wk, 24 wk follow up kg ,Waist circumference Baseline, 1 wk, 4 wk, 12 wk, 24 wk follow up inch,Fat mass Baseline, 1 wk, 4 wk, 12 wk, 24 wk follow up Bioimpedence ,Xray film at L4 level baseline, 1 wk follow up Determine fat mass

Secondary

MeasureTime frame
Safety 1st-10th treatment, 1 wk, 12 wk, 24 wk follow up Adverse event,Patient Improvement scale Baseline, 1 wk, 4 wk, 12 wk, 24 wk follow up percent improvement,Physician Improvement scale Baseline, 1 wk, 12 wk, 24 wk follow up percent improvement

Countries

Thailand

Contacts

Public ContactRungsima Wanitphakdeedecha

Faculty of Medicine Siriraj Hospital, Mahidol University

rungsima.wan@mahidol.ac.th024197000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026